Neuropathological validation of plasma GFAP

Glial fibrillary acidic protein (GFAP) is an astrocytic marker that has been recently associated with fluid and imaging biomarkers of amyloid and tau pathologies in the Alzheimer’s disease (AD) spectrum. Plasma GFAP has also shown to be a strong indicator of early brain amyloidosis in preclinical AD. However, it remains to be confirmed how plasma GFAP associates with neuropathological hallmarks of AD and which pathological entities are being reflected by this plasmatic marker.